The patient's reluctance to take insulin regularly and frequent non-attendance at the clinics was cited as reasons for his poor glycaemic control. Anti-glutamic acid antibodies (GAD) were negative. In view of the family history, hepatocyte nuclear factor-1 alpha (HNF1a) maturity-onset diabetes of the young (MODY) was considered. Molecular genetic analysis showed a missense mutation S145L in exon 2 of HNF-1a gene. In view of known sensitivity of HNF-1a MODY patients to sulphonylureas, insulin was discontinued and a therapeutic trial of low-dose gliclazide, 40 mg twice daily, initiated. A dramatic improvement in glycosylated haemoglobin was observed (Figure 1 ), which was maintained in a subsequent clinic review.
Case 2
A 39-year-old resuscitation officer with a body mass index of 26 self-presented with a high capillary blood glucose level. The patient reported that her mother, two maternal uncles and maternal grandfather were diagnosed with 'diet-controlled type 2 diabetes'. A fasting plasma glucose was 7.3 mmol/l with a glycosylated haemoglobin (HbA1c) level of 6%. An oral glucose tolerance test showed a fasting glucose of 6.5 mmol/l and a two-hour Diagnosis in diabetes: does it matter?
aBsTRaCT The diagnosis of diabetes subtypes in a busy clinic is usually based on the age at onset, phenotype and biochemical diagnostic criteria. Not surprisingly, the focus is predominantly on diagnosing type 1 and type 2 diabetes. More challenging for the physician is to think of monogenic diabetes, which results from gene mutations that reduce beta cell function. Often misdiagnosed as type 1 or type 2 diabetes, maturity-onset diabetes of the young (MODY) is the most common form of monogenic diabetes, accounting for 1-2% of all diabetes cases. A diagnosis of monogenic diabetes has important implications in treatment, the prediction of disease progression and screening of family members. We highlight two cases of monogenic diabetes, where the diagnosis had significant implications in all the above parameters. This is followed by a discussion on the glucokinase and hepatocyte nuclear factor-1 alpha MODY, which together constitute the most frequent cause of MODY syndromes in all populations.
KeywoRds Diabetes, maturity-onset diabetes of the young, molecular genetics deClaRaTion of inTeResTs No conflict of interests declared. value of 7.3 mmol/l. The patient was negative for GAD, a marker for type 1 diabetes. Molecular genetic testing in view of the above features showed her to be heterozygous for a missense mutation S340I in exon 8 of the glucokinase (GCK) gene. This results in a substitution of amino acid isoleucine for serine at codon 340, consistent with a diagnosis of MODY, subtype glucokinase. The patient continues to do well on no medications for diabetes and she is followed up annually for glycaemic control and microvascular complications.
disCussion
In 1974, Tattersall described three families with dominantly inherited diabetes, who could be treated with sulphonylureas after 40 years of diagnosis. 1 In the same year, Tattersall and Fajans coined the acronym MODY, which was defined as 'fasting hyperglycaemia diagnosed under age 25 years which could be treated without insulin for more than two years'.
Maturity-onset diabetes of the young describes a clinically heterogenous group of dominantly inherited disorders with onset usually before 25 years of age, presenting as non-ketotic diabetes mellitus, due to mutations in genes that result in defective beta cell function. The mutations affect genes encoding GCK, a rate-limiting glycolytic enzyme, or those that encode five other transcription factors, of which HNF-1a and HNF4a are the most relevant to everyday clinical practice. Monogenic diabetes caused by such mutations accounts for approximately 1-2% of all diabetes cases. 2 Mutations in GCK and HNF-1a are the most common causes of monogenic diabetes. 3 There are certain features in the history and biochemistry that should alert the physician to the possibility of monogenic diabetes (Table 1) . With GCK mutations, the predominant feature is the presence of persistent fasting hyperglycaemia (5.5-8 mmol/l) that is stable for months or years. 4 Glucokinase catalyses the first rate-limiting step of glycolysis and determines the rate of adenosine triphosphate (ATP) production in response to the blood glucose concentration. Mutations in the GCK gene reduce the efficiency of the pancreatic beta cell to use glucose for ATP production, thereby leading to higher than normal blood glucose to trigger insulin release. An oral glucose tolerance test (OGTT) in such patients typically shows, as in Case 2, a small increment in the two-hour glucose, usually less than 3 mmol/l 4 and an HbA1c that rarely exceeds 7.5%. A diagnosis of GCK MODY in our patient had important implications for her prognosis and treatment. Patients with such mutations rarely suffer from microvascular complications and treatment with oral agents or insulin rarely affects HbA1c. 5 Mutations in HNF-1a gene are the most common form of MODY syndromes. 3 Physicians should have a high index of suspicion if the patient presents with diabetes at less than 25 years of age, has a strong family history of both type 1 and type 2 diabetes and has a greater than 5 mmol/l increment on the two-hour glucose value on an OGTT, 4 a low renal threshold 6 with glycosuria at blood glucose values less than 10 mmol/l and a marked sensitivity to sulphonylureas. 7, 8 Hepatocyte nuclear factors (HNF-1a, HNF-4a and HNF-1a) are a network of transcription factors that regulate insulin gene expression 9, 10 and therefore insulin secretion. Unlike GCK mutations, the hyperglycaemia in HNF-1a mutation tends to worsen with time and patients may develop the full spectrum of complications, as in case 1. Patients with HNF-1a MODY, even those with a long duration of diabetes as in our case, respond dramatically to sulphonylureas 8 and this should therefore be considered as the initial treatment of choice. The reason for the sulphonylurea sensitivity may relate to the fact that the beta cell defect in HNF-1a MODY is upstream of the sulphonylurea receptor with a preservation of the signalling pathway downstream of the receptor. 7 A prompt diagnosis in our patient (case 1) and an early institution of sulphonlyurea therapy might have prevented, or at least delayed, the development of sight-threatening retinopathy and overt diabetic nephropathy. 
